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Toxic lesion of the liver is frequently a subject of differential diagnosis analysis of 
infectologists-hepatologists. The problem is being greatly increased by prescribed 
medicaments use and during self-treatment practice.  
Liver damage mostly goes as cholestatic form of disease, with clinical manifestations 
of icterus, pruritus, changes of urine and stool color. Clinical finding is followed by 
characteristic laboratory findings (bilirubin, alkaline phosphatase, gamma-glutamyl 
transpeptidase, cholesterol). In order to make complete diagnostic of these patients, it is 
often necessary to perform a liver biopsy and pathohistological examination of liver tissue. 
A 42-year-old female patient with cholestatic elements was examined, and the liver biopsy 
was performed after her clinical and laboratory examinations, when the toxic character of 
liver damage was confirmed. Acta Medica Medianae 2009;48(2):49-51. 
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Introduction  
 
As a central organ of the human organism 
the liver has multiple functions, including metabolism 
of different substances as well as medicaments. 
Medicaments are taken into the human organism, 
either on physician’s recommendation or as self-
treatment practice. Different lesions of the liver 
may occur during drugs intakes as a consequence 
of an irregular dosing or individual idiosyncrasy (1-
5). More precisely, liver damage develops as a 
direct hepatotoxic injury of hepatocytes, trough 
hepato-sensitisation or by the both mechanisms 
together. Hepatitis medicamentosa is a rare 
condition, it is present in 1-3% of patients with 
hepatitis, while up to 30% of all fulminant 
hepatitides are accounted for drug caused lesions 
(2, 6). Essentially, an effect of psychopharmaceutical 
drugs influence on cytokines production, the major 
humoral mediators of inflammation and infection 
(7). Proinfective cytokines, tumor necrosis factor-
alpha, interleukin beta 1 and interleukin 6 are 
released by kupffer cells or activated neutrophils 
and macrophages, they initiate hepatic cells 
defense mechanism, including activation of 
apoptosis. Reactive oxygen and nitrogen forms, 
generated in the response to cytokine induced 
stress signals in the liver parenchyma and by 
kupffer and inflammatory cells, mobilize the cells 
defense mechanism (inflammatory response and 
neutrophils infiltration) (8). Drug-induced liver 
damage develops during a treatment with large 
number of medicaments or when the treatment 
course is repeated. It can be acute or chronic 
depending on the liver damage duration (3). 
Large number of drugs may cause liver damage. 
Drug-induced liver damage may be asymptomatic 
or with maculopapular rash, itching, fever, chills, 
nausea, vomiting, loss of appetite, jaundice, dark 
urine, acholic stools, gingivorrhagia, hepatomegaly, 
pain under the right costal arch, diarrhea, 
abdominal pain, spider naevi and abdominal free 
fluid (9). Drug-induced liver damage is followed 
by increased levels of bilirubin, ALP, gamma GT, 
cholesterol, aminotransferases and eosinophils 
(2). Pathohistological examinations show focal 
necrosis of hepatocytes, cholestasis, periportal 
mononuclear and eosinophil cells infiltration (3). 
Hepatitis medicamentosa ends with a recovery, 
although it may progress into a chronic hepatitis 
or an acute liver failure with a lethal outcome (2). 
Hepatitis caused by medicaments is diagnosed with 
anamnestic data of drugs intake, clinical examination, 
laboratory findings, and not rarely, with a 
pathohistological confirmation. Therapeutic approach 
is based on an intake cessation of medicament 
that caused damage, and also on a substitutional 
and symptomatic therapy. 
 
The aims of the study        
 
T h e  a i m s  o f  t h i s  s t u d y  w e r e  t o  c l e a r l y  
highlight the possible role and position of 
medicaments leading to a damage of the liver as 
a central organ of the human body, forms of its 
clinical manifestations, the liver dysfunction after 
an use of different medicaments (antidepressants, 
analgesics) and to review differential diagnostic 
difficulties in a clinician’s work with these patients. 
 
Case presentation 
 
A female patient P.Z. was born in 1966. 
She works as a laborer and was hospitalized on 13
th 
of May 2008. 
Among her complaints dominant were: 
nausea, dull pain under the right rib arch, fatigue, 
dark urine, yellowish staining of skin and mucousas 
and itching all over the body. Between 02. and 13. 
of May 2008. the patient was hospitalized in the 
Health center in Vranje with a diagnosis of Hepatitis 
virosa acuta.  
After her laboratorical and clinical findings 
got worse, together with negative results for viral 
hepatitis A or B infection, with a clinic’s doctor 
approval, she was transferred to the Clinic for Hepatitis toxica – case report                                                                        Velimir Kostić i sar. 
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infectious diseases with a diagnosis of Hepatitis 
toxica cholestasis in obs.  
The anamnestic data show that since 2nd 
of April patient was under the treatment for: 
neurotic reactions (anxious-subdepressive type), 
hemiparesis lat. dex. disc. inverterata, artralgia 
artic. Temporomandibularis bil., neuralgia n. trigemini 
sec., Sy. cervicobrachialis et cervicobasilaris, 
Discarthrosis C3-C4, c5-C6, C6-C7 susp., Neuralgia 
n. intercostalis bil. pp. lat. sin., Kyphoscoliosis 
thorac. alias, Lumboischiagia bil. pp. lat. dex. 
sympt., Dyscarthrosis L3-L4, L4-L5, L5-S1 susp., 
hypertensio artrerialis non fixata, gastritis chronica 
hyperacida, myalagia m. recti abdominalis bil.   
Because of these diagnoses patent was 
treated in private surgery for neurology and 
general medicine, with the following therapy: 
Maprotilin tab. à 25 3x1, Largactil tab. à 25, 
1+1+2 schedule, Rivotril tab. 2 mg 1 in the 
evening, Flugalin tab. à 50 3x1, amp. Impletola 
5,0cc (infiltrative), together with hygienic and 
dietary regimens and strict bed rest. 
On the admission the patient was conscious, 
oriented, afebrile, average osteomuscular body 
build, skin and mucosas were intensively yellow. 
The liver was palpable at the right costal arch. 
Laboratory tests were immediately performed the 
next day (13.05.08), and these were the results: 
WBC 10.1, ne 57.9%, ly 30.6%, mo 6.6%, eo 
4%, ba 0.9%, RBC 3.42, HGB 108, HCT 33, PLT 
449, SE 46, AST 549, ALT 898, direct bilirubin 
218, total bilirubin 102.4, ALP 518, cholesterol 
21, gamma GT 642.9, triglycerides 2.62, alpha 
FP 3.34, fibrinogen 7.02, ANA, AGMA, ATA and 
AMA were negative, PTV 114%, aPTT 29, T3 
0.88, T4 63.85, TSH 3.126. Upper abdomen 
ultrasound shows the normal liver position and 
size, with a slightly increased ehogenicity, with 
no focal lesions. Gall-bladder is without pathological 
findings. Bile ducts are not visible. The spleen is 
normal in size and homogenous.  
Both kidneys have signs of microlithiasis 
without an obstruction. On May 19
th, laboratory 
findings were following: Se 62, WBC 15.4, ne 
64.9%, ly 23.6%, mo 0,75%, RBC 3.53, HGB 
114, HCT 0.343, PLT 651, direct bilirubin 38.8, 
total bil. 88.5, ALP 586, gamma GT 824, proteins 
70.3, albumins 39.4.  
On May 23
rd results were: AST 169, ALT 
624, direct bil. 28.8, total bil. 69.4, LDH 508.5, 
ALP 542, gamma GT 908.5, cholesterol 16.37, ldl 
12.34, hdl 2.36, triglycerides 3.43, proteins 69, 
albumins 40.3, LE cells 0, Fe 15.9. An 
ophthalmologist excluded existence of Keiser-
Fleisher ring: Cu 25.98, ceruloplazmin 400.9, 
HBsAg neg., fibrinogen 5, CRP 5.8, CK 2.6.  
On 24
th of May, the patient was sent to a 
gastroenterologist and hematologist. The gastro-
enterologist confirmed our working diagnosis - 
cholestasis, hepatitis tox. PBC susp. He suggested 
t h a t  E R C P  o r  M R C P  s h o u l d  b e  p e r f o r m e d .  A t  t h e  
same time, the hematologist gave his diagnosis: 
hepatopathia, PBC and trombocytaemia.  
For now, there are no indications for an 
idiopathic thrombocytosis and the causes of 
secondary thrombocytosis should be excluded. 
Immune complexes were negative on 26th of 
May. On May 28
th, the patient’s analyses were 
repeated: se 54, wbc 8.4, ne 52.84, ly. 29.9, eo 
6.3, mo 9.5, rbc 3.68, hgb 119, hct 35.8, plt 442, 
ast 294, alt 831, bil. dir. 20.6, total bil. 49, ALP 
438, cholesterol 9.8, ldl 2.08, hdl 6.86, ldh 686, 
proteins 70.5, albumins 40.4, PTV 86%, aPTT 
30”, TV 17”, FK I 782. On 6
th June, a punctional 
biopsy of the liver was performed, when the 
diagnosis of cholestasis, lesio hepatitis toxica was 
established. The morphological finding of the 
biopsy indicated a cholestatic type of toxic liver 
damage. 
During the hospitalization, patient underwent 
an intensive medicament treatment with 
corticosteroids, vitamin K, fluids, choleretics, 
ranisan, aspirin, lentostamin, kardiopirin, along 
with constant biohumoral monitoring. Patient was 
released home after 25 days, with a suggestion 
to continue the therapy with: Ursosan 3x2, 
Oligovit 2x1 and diet that Clinic for dietetic of the 
Public health institute recommended.  
Six months after the discharge the 
patient had following laboratory results: WBC 
10.7 G/L, ly 2.7 G/L, mid 0.6 G/L, gr 7.4 G/L, 
RBC 4.19 T/L, Hgb 131 mg%, Hct 377, PLT 321 
G/L, AST 37 UI/L, Alt 38 UI/L, bil. 6.3 mmol/l, 
Alp 118 UI/L, gamma GT 68 UI/L, cholesterol 
5.83 mmol/l, triglycerides 2.06 mmol/l, alpha-
fetoprotein 3.44. Subjectively, the patient still 
feels some discomfort under the right rib arch 
and occasional abdominal distensions. Upper 
abdominal ultrasound is not showing any 
pathological finding, except the nephrolitiasis 
with no urine stasis. 
 
Discussion 
 
The patient P.Z. was treated for her 
neuropsychiatric difficulties by the neuropsychiatrist. 
On the basis of the clinical examination the patient 
underwent the treatment in intention to achieve 
rehabilitation. Polymorphism of the clinical problems 
has probably affected a variety and a number of 
recommended medicaments. Prescribed medicaments 
had antidepressive and analgesic action. During and 
after the course of treatment, the patient developed 
clinical manifestations of an acute liver damage. 
Among registered problems dominant were 
dyspeptic syndrome, icterus, pruritus and other. 
This clinical finding was also described by other 
authors, in which patients used similar or 
different drugs (4,5,7,10). Type of liver damage 
in these patients may be cholestatic, hepatotoxic 
or mixed (1,2,4,5). Our patient had a mixed type 
of liver damage (icterus, dark urine, hypocholic 
stool, pruritus). This finding had laboratorical 
confirmation, when the elevated values of 
bilirubin, cholesterol, alkaline phosphatase, 
glutamil transpeptidase, triglycerides were found, 
as well as significant elevation of amino-
transferase level. Similar finding was noted by 
other authors in their reviews (3,6,11,12). The 
observed clinical-biochemical presentation makes 
a clinician wonder if there is a possibility of liver 
damage by some other agents (infective, 
immunological, malignant or other). In that 
order, further examinations were performed, with 
the objective to eliminate the suggested 
etiological factors of liver damage (12,13). Due 
to the intensive cholestasis, medical preparations 
were administered to lower the level of 
cholestatic enzymes on the one hand and 
concomitant clinical problems on the other. Acta Medica Medianae 2009, Vol.48(2)                                     Hepatitis toxica – case report 
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Beside that, due to the initial inadequate therapeutic 
response, an aspiration liver biopsy was preformed 
and the obtained pathohistological finding confirmed 
a drug-induced liver damage. Further laboratory 
monitoring of the patient provide no elements that 
would indicate on a chronic evolution of the liver 
damage, as it is described by other researchers 
(10,12,14,15). The disease had prolonged course 
with a tendency of settling down. At the same 
time, during the hospital treatment of the 
patient, parameters that would indicate on a 
serious hepatocytes insufficiency or even a sign 
of an unfavorable disease progression were not 
observed, as other authors describe in similar 
situations (11,15). 
  
Conclusion 
 
1. A treatment with various medicaments 
carries a risk of liver damage, that may be different 
in type. 
2. The most frequent type of liver damage is 
mixed type, which is also considered in   
differentional diagnosis of immunological, infectious 
and other diseases. 
3. Pathohistological examination of affected 
liver represents the most reliable diagnostic 
procedure in resolving diagnostic dilemmas. 
4 .  A n a m n e s t i c  d a t a  o f  previous drugs intake 
are very important, because they can represent an 
inevitable etiological factor of developed disorders.  
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HEPATITIS TOXICA-PRIKAZ BOLESNIKA  
 
Velimir Kostić, Gordana Trifunović, Marina Đorđević, Branislav Jovanović, 
Jovana Đorđević, Jelena Radović i Lidija Popović 
 
Toksično oštećenje jetre često je predmet diferencijalno dijagnostičkog ispitivanja 
infektologa hepatologa. Problem se u velikoj meri uvećava unosom propisanih medika-
manta kao i njihovim unosom tokom takozvanog samolečenja.  
 
Oštećenje jetre najčešće protiče po tipu holestazne forme bolesti sa ispoljenim 
kliničkim manifestacijama tipa žutila, pruritusom, promenom boje mokraće i stolice. 
Klinički nalaz je praćen i karakterističnim laboratorijskim nalazom (bilirubin, alkalna 
fosfataza, glutamil transpetidaza, holestrol i drugo). U cilju potpune dijagnostike ovakvih 
bolesnika neophodno je često uraditi biopsiju jetre sa pratećom patohistološkom obradom 
uzetog materijala. Ispitivana je 42-godišnja bolesnica sa elementima holestaze, kod koje 
se posle kliničkog i laboratorijskog ispitivanja pribeglo biopsiji jetre, čime je potvrđen 
toksični karakter oštećenja jetre. Acta Medica Medianae 2009;48(2):49-51. 
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